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Abstract 
This thesis reports a study of the chemical stability and coordination chemistry 
of several antitumour metallocenes Cp2MCl2 (Cp = h5-C5H5; M = Ti 1, V 2, Nb 3, 
Mo 4), as well as derivatives of Cp2TiCl2 1, with nucleic acids, nucleic acid constituents 
and proteins.   These studies were carried out in order to identify the biologically active 
species and more fully understand the molecular level mechanism of action of the 
antitumour metallocenes, in particular Cp2TiCl2 1, which is currently undergoing 
phase II clinical trials.  
The interactions of Cp2MoCl2 4 with four oligonucleotides were studied by 1H 
and 31P NMR spectroscopy.  In 50 mM salt solutions of Cp2MoCl2 4, hydrolysis of the 
halide ligands occurred to give a solution with pD ~2, containing a species in which 
both Cp rings remain metal bound for 24 h.  At pD ~7, partial hydrolysis of the Cp rings 
(~30%) occurred after 24 h.  Addition of an aqueous solution of Cp2MoCl2 4 in 50 mM 
salt to the self-complementary sequence d(CGCATATGCG)2, maintaining the pD at 
6.0-7.0, showed no evidence for the formation of a metallocene-oligonucleotide 
complex and only peaks arising from hydrolysis of Cp2MoCl2 4 were detected.  A 
similar result was obtained in titration experiments with the single stranded sequence 
d(ATGGTA) at pD 6.5-7.0.  However, at pD 3.0, new signals assigned to a 
molybdocene-oligonucleotide complex(es), which was stable for hours at pD 3.0, were 
detected; while at pD ~7 the complex is destabilised and only peaks arising from 
hydrolysis of Cp2MoCl2 4 were detected.  Titration experiments at low pD with 
Cp2MoCl2 4 and the dinucleotide dCG were consistent with formation of a complex 
arising due to coordination of molybdenum to guanine N7 and/or cytosine N3.  The 
results obtained showed that stable oligonucleotide adducts were not formed in 50 mM 
salt at pD ~7 and hence it is highly unlikely that formation of molybdocene-DNA 
adducts in vivo is the primary action that is responsible for the antitumour properties of 
Cp2MoCl2 4. 
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The rate of hydrolysis of the aromatic rings of Cp2TiX2 (X = Cl 1, 
OCOCH2NH3Cl 27) and the dimethylsubstituted derivatives (MeCp)2TiX2 (X = Cl 34, 
OCOCH2NH3Cl 41), in aqueous solutions at pD 2-8 was studied by 1H NMR 
spectroscopy.  Rapid hydrolysis of both the halide/glycine and Cp ligands in Cp2TiX2 
(X = Cl 1, OCOCH2NH3Cl 27) occurred and predominantly gave a precipitate at pD ~7.  
In contrast, under the same experimental conditions, the predominant species present in 
aqueous solutions of (MeCp)2TiX2 (X = Cl 34, OCOCH2NH3Cl 41) at pH 2-8 contained 
both MeCp rings metal bound.  At pD < 5, Cp2TiX2 (X = Cl 1, OCOCH2NH3Cl 27) and 
(MeCp)2TiX2 (X = Cl 34, OCOCH2NH3Cl 41) formed similar complex(es) with purine 
nucleotides.  However, at pD >5, stable adducts between nucleotides and Cp2TiX2 
(X = Cl 1, OCOCH2NH3Cl 27) were not formed.  In contrast, (MeCp)2TiX2 (X = Cl 34, 
OCOCH2NH3Cl 41) formed complex(es) with 5'-dAMP or 5'-dGMP, which were stable 
for 24 h.  These results suggest that formation of stable chelates between (MeCp)2TiX2 
(X = Cl 34, OCOCH2NH3Cl 41) and nucleic acid constituents in vivo is possible.  
However, the methyl substituted derivatives 34 and 41 did not show any antitumour 
activity against EAT in mice when administered in either 10%DMSO/90%saline or in 
water at pH 6.2-6.4, which suggests that the labile Cp-Ti bond present in Cp2TiCl2 1 is 
required for antitumour activity. 
The synthesis of a range of Cp substituted titanocene derivatives was 
investigated in an attempt to prepare derivatives with modified Cp stability in 
comparison to the methyl substituted derivatives.  The synthesis of derivatives 
(CpCH2Y)2TiCl2 where Y = -CHO 43, -CONMe2 44, -NO2 45, (RCp)2TiCl2 where R = 
-COMe 46, -COOMe 47 or -CONMe2 48, (CpNMe2)2TiCl2 62 and 
(Cp(CH2)2NMe2)2TiCl2 63 was unsuccessful, due to the presence of coordinating 
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substituents on the Cp rings and poor stability in polar, protic solvents.  Hence, these 
derivatives were excluded from further studies. 
The rate of hydrolysis of the Cp rings of Cp2TiX2 (X = Cl 1, OCOCCl3 22 and 
OCOCH2NH3Cl 27) in aqueous solutions, 10%DMSO/90%D2O and 100% DMSO was 
monitored by 1H NMR spectroscopy.  Rapid hydrolysis of both the carboxylate and Cp 
ligands of Cp2TiX2 (OCOCCl3 22 and OCOCH2NH3Cl 27) occurred in DMSO to give 
biologically inactive species.  The rate of these reactions were concentration dependent 
as dilution of these samples with saline or water to give the therapeutic conditions of 
10%DMSO/90%D2O slowed the hydrolysis chemistry.  In contrast, samples of Cp2TiX2 
(X = Cl 1 and OCOCH2NH3Cl 27) dissolved in water, gave solutions containing the 
presumed antitumour active species in which the halide or glycine ligands have been 
hydrolysed but the Cp rings remain metal bound.  Thus, charged X ligands may be 
incorporated into Cp2TiX2 and will give comparable activity to Cp2TiCl2 1 provided the 
samples are administered in water.   
The antitumour metallocenes Cp2MCl2 (M = Ti 1, V 2, Nb 3,  Mo 4) and the 
inactive derivative (MeCp)2TiCl2 34 were found to inhibit the relaxation of supercoiled 
plasmid DNA pBR322 by human topoisomerase II in vitro.  These results implicated 
the inhibition of topoisomerase II in the mechanism of antitumour activity although 
there was no direct correlation between the in vitro results with biological activity 
against EAT in vivo.   
UV spectroscopy confirmed that the metallocenes Cp2MCl2 (M = Ti 1, Mo 4) 
became associated with and were stabilised to hydrolysis by calf thymus DNA but not 
with human serum albumin.  ICP-AES was used to measure the amount of metal 
associated with either DNA or human serum albumin after incubation with Cp2MCl2 
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(M = Ti 1, Nb 3, Mo 4) and dialysis of these solution.  The results confirmed that DNA 
stabilises or becomes associated with the metallocenes.  However, errors associated 
with the ICP-AES measurements did not allow these results to be quantified.  1H NMR 
spectroscopy was used to show that the antitumour metallocene Cp2MoCl2 4 formed an 
adduct with glutathione 72 in the pH range 3-7 through the sulfur donor group.  In 
comparison, the antitumour metallocenes Cp2MCl2 (M = Ti 1, Nb 3) showed limited 
adduct formation with glutathione 72 at pH ~3 and no adducts were detected at 
pH > 5.5.  
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Abbreviations 
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